Large-scale production of pharmaceutical proteins in plant cell culture-the protalix experience

Yoram Tekoah; Avidor Shulman; Tali Kizhner; Ilya Ruderfer; Liat Fux; Yakir Nataf; Daniel Bartfeld; Tami Ariel; Svetlana Gingis-Velitski; Uri Hanania; Yoseph Shaaltiel

doi:10.1111/pbi.12428

Large-scale production of pharmaceutical proteins in plant cell culture-the protalix experience

Yoram Tekoah, Avidor Shulman, Tali Kizhner, Ilya Ruderfer, Liat Fux, Yakir Nataf, Daniel Bartfeld, Tami Ariel, Svetlana Gingis-Velitski, Uri Hanania, Yoseph Shaaltiel

Research output: Contribution to journal › Review article › peer-review

116 Scopus citations

Abstract

Protalix Biotherapeutics develops recombinant human proteins and produces them in plant cell culture. Taliglucerase alfa has been the first biotherapeutic expressed in plant cells to be approved by regulatory authorities around the world. Other therapeutic proteins are being developed and are currently at various stages of the pipeline. This review summarizes the major milestones reached by Protalix Biotherapeutics to enable the development of these biotherapeutics, including platform establishment, cell line selection, manufacturing process and good manufacturing practice principles to consider for the process. Examples of the various products currently being developed are also presented.

Original language	English
Pages (from-to)	1199-1208
Number of pages	10
Journal	Plant Biotechnology Journal
Volume	13
Issue number	8
DOIs	https://doi.org/10.1111/pbi.12428
State	Published - 1 Oct 2015
Externally published	Yes

Keywords

Enzyme replacement therapy
Molecular farming
Oral delivery
Plant cell culture
Protalix Biotherapeutics
β-glucocerebrosidase

ASJC Scopus subject areas

Biotechnology
Agronomy and Crop Science
Plant Science

Access to Document

10.1111/pbi.12428

Cite this

@article{f986a0899c424597908f9cc0749c5b66,

title = "Large-scale production of pharmaceutical proteins in plant cell culture-the protalix experience",

abstract = "Protalix Biotherapeutics develops recombinant human proteins and produces them in plant cell culture. Taliglucerase alfa has been the first biotherapeutic expressed in plant cells to be approved by regulatory authorities around the world. Other therapeutic proteins are being developed and are currently at various stages of the pipeline. This review summarizes the major milestones reached by Protalix Biotherapeutics to enable the development of these biotherapeutics, including platform establishment, cell line selection, manufacturing process and good manufacturing practice principles to consider for the process. Examples of the various products currently being developed are also presented.",

keywords = "Enzyme replacement therapy, Molecular farming, Oral delivery, Plant cell culture, Protalix Biotherapeutics, β-glucocerebrosidase",

author = "Yoram Tekoah and Avidor Shulman and Tali Kizhner and Ilya Ruderfer and Liat Fux and Yakir Nataf and Daniel Bartfeld and Tami Ariel and Svetlana Gingis-Velitski and Uri Hanania and Yoseph Shaaltiel",

note = "Publisher Copyright: {\textcopyright} 2015 Society for Experimental Biology, Association of Applied Biologists and John Wiley & Sons Ltd",

year = "2015",

month = oct,

day = "1",

doi = "10.1111/pbi.12428",

language = "English",

volume = "13",

pages = "1199--1208",

journal = "Plant Biotechnology Journal",

issn = "1467-7644",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "8",

}

TY - JOUR

T1 - Large-scale production of pharmaceutical proteins in plant cell culture-the protalix experience

AU - Tekoah, Yoram

AU - Shulman, Avidor

AU - Kizhner, Tali

AU - Ruderfer, Ilya

AU - Fux, Liat

AU - Nataf, Yakir

AU - Bartfeld, Daniel

AU - Ariel, Tami

AU - Gingis-Velitski, Svetlana

AU - Hanania, Uri

AU - Shaaltiel, Yoseph

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Protalix Biotherapeutics develops recombinant human proteins and produces them in plant cell culture. Taliglucerase alfa has been the first biotherapeutic expressed in plant cells to be approved by regulatory authorities around the world. Other therapeutic proteins are being developed and are currently at various stages of the pipeline. This review summarizes the major milestones reached by Protalix Biotherapeutics to enable the development of these biotherapeutics, including platform establishment, cell line selection, manufacturing process and good manufacturing practice principles to consider for the process. Examples of the various products currently being developed are also presented.

AB - Protalix Biotherapeutics develops recombinant human proteins and produces them in plant cell culture. Taliglucerase alfa has been the first biotherapeutic expressed in plant cells to be approved by regulatory authorities around the world. Other therapeutic proteins are being developed and are currently at various stages of the pipeline. This review summarizes the major milestones reached by Protalix Biotherapeutics to enable the development of these biotherapeutics, including platform establishment, cell line selection, manufacturing process and good manufacturing practice principles to consider for the process. Examples of the various products currently being developed are also presented.

KW - Enzyme replacement therapy

KW - Molecular farming

KW - Oral delivery

KW - Plant cell culture

KW - Protalix Biotherapeutics

KW - β-glucocerebrosidase

UR - http://www.scopus.com/inward/record.url?scp=84942193222&partnerID=8YFLogxK

U2 - 10.1111/pbi.12428

DO - 10.1111/pbi.12428

M3 - Review article

AN - SCOPUS:84942193222

SN - 1467-7644

VL - 13

SP - 1199

EP - 1208

JO - Plant Biotechnology Journal

JF - Plant Biotechnology Journal

IS - 8

ER -

Large-scale production of pharmaceutical proteins in plant cell culture-the protalix experience

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this